This prospective, national, multi-centre study will include patients with stage III triple-negative breast cancer (TNBC) who are planned to start with standard (neo)adjuvant systemic treatment. The study will gather clinico-pathological, treatment and follow-up information of participating patients through Dutch databases. Participating patients will be asked to complete cancer specific and more generic quality of life questionnaires at nine time points during and after their anticancer treatment in a mobile application.
For all patients who have consented to additional blood collection, to assess the course of dynamic ctDNA during (neo)adjuvant chemotherapy and its relation with outcome, two tubes will be collected at four different time points.
Patients aged 18 years or older
Histologically confirmed adenocarcinoma of the breast
Assumed clinical or pathological stage III (TNM) breast cancer
HER2-negative: i.e. either score 0 or 1 at immunohistochemistry or score 2 at immunohistochemistry and negative at in situ hybridization (ISH, CISH or FISH)
Evidence of distant metastases. Staging examinations should have been performed according to Dutch national guidelines.
Patients who are only treated systemically in the adjuvant setting
Participation in another clinical study with an treatment intervention during the course of this study.
The Netherlands Cancer Institute
Lead sponsor
Dutch Cancer Society
Collaborator